Poland· PL-100122792
Morfeo
A zaleplon product containing zaleplonum, registered in Poland by Adamed Pharma S.A.. The same ATC class is registered in 5 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Zaleplon is registered in 5 of 19 countries.
Countries holding a registration under ATC N05CF03 (zaleplon), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 4 of them publish a price we can compare per daily dose
Zaleplon · ATC N05CF03
5 / 19 countries
- Belgiumprice
- Finlandprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Zaleplonum
- Manufacturer
- Adamed Pharma S.A.
- Country
- Poland (PL)
- ATC code
- N05CF03
- ATC class
- Zaleplon
- Defined daily dose
- 10 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05909991056117
- gtin05909990223435
- gtin05909990223442
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
176 interactions on record for zaleplon.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Zaleplon · interactions on record
176 records
- 4 severe
- 72 moderate
- 7 minor
- 83 info
Most severe, free to view
- MorphineN02AA01severe
- MorphinN07BC09severe
- HydrocodoneR05DA03severe
- CodeineR05DA04severe
10 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Zaleplon in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cb414ee1-fef1-4926-a25b-e02912f2f71d GET /v1/drugs/cb414ee1-fef1-4926-a25b-e02912f2f71d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "10 mg",
"packaging": "05909991056117 ¦ Rp ¦ 23080\n30 kaps.\n05909990223435 ¦ Rp ¦ 27292\n10 kaps.\n05909990223442 ¦ Rp ¦ 27293\n20 kaps.",
"substance": "Zaleplonum 10 mg",
"common_name": "Zaleplonum",
"pl_product_id": "100122792",
"pozwolenie_nr": "10561",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about zaleplon.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.